Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + luspatercept for transfusion-dependent bone marrow fibrosis-associated anemia after ruxolitinib failure or intolerance
ChiCTR2400087725Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2024
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor and luspatercept in myelofibrosis (MF), Myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and 1 more, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Red blood cell transfusion independence for at least 8 weeks. Started Aug 2024; status: recruiting.
02
Drugs
selinexorluspatercept
03
Conditions
myelofibrosis (MF)Myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)anemia of myelofibrosis
Beyond the preview
Go deeper on ChiCTR2400087725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087725.